Announcement pursuant to rule 13.51B(2) of the listing rules
Filed with HKEX · Stock code 2185 · · 2 pages · English
Shanghai Bio-heart Biological Technology Co., Ltd. 上海百心安生物技术股份有限公司 (A joint stock company incorporated in the People’s Republic of China with limited liability) (Stock Code: 2185) ANNOUNCEMENT PURSUANT TO RULE 13.51B(2) OF THE LISTING RULES This announcement is made by Shanghai BioHeart Medical Co., Ltd. (the “Company”, together with its subsidiaries, the “Group”) pursuant to Rule 13.51B(2) of the
Shanghai Bio-Heart Biological Technology Co., Ltd. on 6ix
Earlier from Shanghai Bio-Heart Biological Technology
- Voluntary announcement strategic cooperation agreement with shanghai shenqi medical technology co., ltd. to advance the commercialisation of the bioheart bioabsorbable rapamycin-eluting coronary stent system
- Articles of association
Later from Shanghai Bio-Heart Biological Technology
- Notice of 2026 first extraordinary general meeting
- Proposed appointment of independent non-executive director; and (2) notice of 2026 first extraordinary general meeting
- Proxy form for use at the 2026 first extraordinary general meeting to be held on October 9, 2026
- 2026 Interim report
- Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 September 2026
Follow Shanghai Bio-Heart Biological Technology into a list and get an email when it puts out news.
Follow Shanghai Bio-Heart Biological Technology